Susumu Ohwada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Susumu Ohwada has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Yasuo Morishita
56 shared publicationsIzumi Takeyoshi
17 shared publicationsYukio Miyamoto
16 shared publicationsTetsushi Ogawa
14 shared publicationsYoshifumi Tanahashi
11 shared publicationsHideo Shiozaki
8 shared publications
Latest Publications
- Open Access
- 16 February 2007
- Published by Wiley in Cancer Science
- Vol. 98 (4) , 484-490
Immunohistochemical expression of the β‐catenin‐interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER‐2 expression in breast cancers
B9L/BCL9-2, a novel β-catenin-interacting protein, plays an important role in colorectal carcinogenesis by translocating β-catenin to the nucleus and enhancing β-catenin–T-cell factor-mediated transcription. To elucidate the role of B9L in breast cancers, we studied B9L expression in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of the breast immunohistochemically and compared it to the immunohistochemical expression of known proteins involved in breast carcinogenesis. In breast tissues, B9L immunoreactivity was present exclusively in the nuclei of normal and neoplastic ductal cells. In DCIS, immunohistochemical B9L expression was significantly associated with the tumor nuclear grade, comedo necrosis and the expression of ErbB2/HER-2, c-myc and p53. In IDC, B9L expression was correlated with ErbB2/HER-2 expression and tumor nuclear grade only. In both DCIS and IDC, immunohistochemical B9L expression was not related to the expression of cytoplasmic β-catenin. We demonstrated that nuclear B9L expression was closely associated with the high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers. (Cancer Sci 2007; 98: 484–490)
- 16 February 2007
- Published by Wiley in Cancer Science
- Vol. 98 (4) , 484-490
Open AccessImmunohistochemical expression of the β‐catenin‐interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER‐2 expression in breast cancers
B9L/BCL9-2, a novel β-catenin-interacting protein, plays an important role in colorectal carcinogenesis by translocating β-catenin to the nucleus and enhancing β-catenin–T-cell factor-mediated transcription. To elucidate the role of B9L in breast cancers, we studied B9L expression in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of the breast immunohistochemically and compared it to the immunohistochemical expression of known proteins involved in breast carcinogenesis. In breast tissues, B9L immunoreactivity was present exclusively in the nuclei of normal and neoplastic ductal cells. In DCIS, immunohistochemical B9L expression was significantly associated with the tumor nuclear grade, comedo necrosis and the expression of ErbB2/HER-2, c-myc and p53. In IDC, B9L expression was correlated with ErbB2/HER-2 expression and tumor nuclear grade only. In both DCIS and IDC, immunohistochemical B9L expression was not related to the expression of cytoplasmic β-catenin. We demonstrated that nuclear B9L expression was closely associated with the high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers. (Cancer Sci 2007; 98: 484–490)
- Open Access
- 1 February 2007
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 37 (2) , 108-113
Surgical Outcome of Stage III and IV Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs. We report surgical outcome of stage III and IV ACCs. ACCs from seven patients at clinical stage II (n = 1), III (n = 4), or IV (n = 2) were resected. Combined resection of the liver and inferior vena cava was performed in six patients. Morbidity, mortality, recurrence and survival were analyzed. The pathological stage was stage III in five patients and stage IV in two patients. The mortality was zero and the morbidity was two of seven (29%) patients. The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11–58). The mean disease-free survival was 21.0 ± 9.0 months (95% CI: 3.3–38.7). The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively. The mean disease-free survival time was 18.6 ± 6.7 months (95% CI: 5.4–31.8). The most frequent site of metastasis was the lungs, seen in four patients, and liver in three patients. Loco-regional, intra-abdominal lymph node, peritoneum, bone, brain recurrences were also seen in one patient each. The mean survival after recurrence was 19.0 ± 3.3 months (95% CI: 12.6–25.5), and the 50% survival was 18.4 months with mitotan and cytotoxic drug therapy. Resection for stage III, IV ACCs affords the possibility of negative margins, acceptable peri-operative morbidity and mortality, and prolongs survival in selected patients.
- 1 February 2007
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 37 (2) , 108-113
Open AccessSurgical Outcome of Stage III and IV Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs. We report surgical outcome of stage III and IV ACCs. ACCs from seven patients at clinical stage II (n = 1), III (n = 4), or IV (n = 2) were resected. Combined resection of the liver and inferior vena cava was performed in six patients. Morbidity, mortality, recurrence and survival were analyzed. The pathological stage was stage III in five patients and stage IV in two patients. The mortality was zero and the morbidity was two of seven (29%) patients. The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11–58). The mean disease-free survival was 21.0 ± 9.0 months (95% CI: 3.3–38.7). The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively. The mean disease-free survival time was 18.6 ± 6.7 months (95% CI: 5.4–31.8). The most frequent site of metastasis was the lungs, seen in four patients, and liver in three patients. Loco-regional, intra-abdominal lymph node, peritoneum, bone, brain recurrences were also seen in one patient each. The mean survival after recurrence was 19.0 ± 3.3 months (95% CI: 12.6–25.5), and the 50% survival was 18.4 months with mitotan and cytotoxic drug therapy. Resection for stage III, IV ACCs affords the possibility of negative margins, acceptable peri-operative morbidity and mortality, and prolongs survival in selected patients.
- Open Access
- 15 November 2006
- Published by Wiley in Cancer Science
- Vol. 98 (1) , 83-87
Up‐regulation of a BCL9‐related β‐catenin‐binding protein, B9L, in different stages of sporadic colorectal adenoma
Aberrant activation of Wnt signaling is a critical event in the development of human colorectal tumors. The aim of this study was to elucidate the role of B9L and its association with β‐catenin in each stage of the adenoma‐carcinoma sequence of human colorectal tumorigenesis. We investigated the expression levels of B9L in sporadic colorectal adenomas and carcinomas, categorized according to the Vienna classification, using real‐time quantitative polymerase chain reaction (RTQ‐PCR) and immunohistochemical analysis. B9L was expressed in the nuclei of non‐neoplastic colonic mucosa cells and was overexpressed in the nuclei of neoplasias and invasive carcinoma cells. Immunoreactivity to B9L protein was correlated with the progressive grades of colorectal neoplasias, as was the expression of B9L mRNA. A high level of immunoreactivity to nuclear B9L was present in 27% of low‐grade neoplasias and in more than 50% of high‐grade neoplasias and invasive carcinomas, whereas a high level of nuclear B9L immunoreactivity was not observed in any of the non‐neoplastic mucosa samples. The expression of B9L was dramatically increased in low‐grade neoplasias compared with that in non‐neoplastic mucosa. B9L may play an important role in tumorigenesis induced by aberrant activation of Wnt signaling and may act as a key protein in the progressive dysplasia of adenoma. (Cancer Sci 2007; 98: 83–87)
- 15 November 2006
- Published by Wiley in Cancer Science
- Vol. 98 (1) , 83-87
Open AccessUp‐regulation of a BCL9‐related β‐catenin‐binding protein, B9L, in different stages of sporadic colorectal adenoma
Aberrant activation of Wnt signaling is a critical event in the development of human colorectal tumors. The aim of this study was to elucidate the role of B9L and its association with β‐catenin in each stage of the adenoma‐carcinoma sequence of human colorectal tumorigenesis. We investigated the expression levels of B9L in sporadic colorectal adenomas and carcinomas, categorized according to the Vienna classification, using real‐time quantitative polymerase chain reaction (RTQ‐PCR) and immunohistochemical analysis. B9L was expressed in the nuclei of non‐neoplastic colonic mucosa cells and was overexpressed in the nuclei of neoplasias and invasive carcinoma cells. Immunoreactivity to B9L protein was correlated with the progressive grades of colorectal neoplasias, as was the expression of B9L mRNA. A high level of immunoreactivity to nuclear B9L was present in 27% of low‐grade neoplasias and in more than 50% of high‐grade neoplasias and invasive carcinomas, whereas a high level of nuclear B9L immunoreactivity was not observed in any of the non‐neoplastic mucosa samples. The expression of B9L was dramatically increased in low‐grade neoplasias compared with that in non‐neoplastic mucosa. B9L may play an important role in tumorigenesis induced by aberrant activation of Wnt signaling and may act as a key protein in the progressive dysplasia of adenoma. (Cancer Sci 2007; 98: 83–87)
- 1 October 2006
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 49 (10) , 1602-1610
Preoperative Tegafur Suppositories for Resectable Rectal Cancer: Phase II Trial
Ast 14 days were piloted. Methods: A total of 129 patients with resectable rectal cancer were enrolled. The primary end points were pathologic response, adverse events, rate of sphincter-sparing surgery, recurrence, and survival. Results: The total dose of tegafur ranged from 21 to 78 (mean, 32) g. The anal sphincter was preserved in 60.5 percent with microscopic no residual tumor (R0). The overall morbidity rate was 32 percent. Wound infection occurred in 13.2 percent of cases and anastomotic leakage in 9 percent of cases. Pathologic responses were observed in 70 percent of patients, with a complete necrosis occurring in 3.9 percent, two-thirds or more necrosis in 6.2 percent, one-third or more but less than two-thirds necrosis in 18.6 percent, and less than one-third necrosis in 41.9 percent. The mean total dose that patients showing complete or two-thirds or more necrosis received was 42.8 ± 6.4 g (P= 0.01) compared with 31.6 ± 1.2 g administered to patients showing less than two-thirds necrosis. Adverse events were observed in 15.6 percent of patients overall, and Grade III or IV events were observed in 2.3 percent of patients. During a median follow-up of 48 months, distant metastasis occurred in 14.7 percent of patients and local recurrence occurred in 6.2 percent of patients. The four-year, disease-free and overall survival rates were 67.6 and 80.1 percent, respectively. Conclusions: Preoperative tegafur suppositories are associated with low toxicity and may lead to analsphincter-sparing surgery with acceptable postoperative complications and favorable local and distal control. Supported in part by the Harnasou Foundation Fund subsidizing Cancer Research in Harunamachi, the Kanetsu Chuo Hospital Research Fund, the Maebashi Norte Hospital Research Fund, the Kato Medical and Surgical Hospital Research Fund in Maebashi, and the Research Fund of the Uchida Clinic in Inamachi, Saitama. Presented in part at the meeting of the American Society of Clinical Oncology, Orlando, FL, May 18 to 21, 2002. E-mail: sohwada@med.gunma-u.ac.jp © The ASCRS 2006...
- 1 October 2006
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 49 (10) , 1602-1610
Preoperative Tegafur Suppositories for Resectable Rectal Cancer: Phase II Trial
Ast 14 days were piloted. Methods: A total of 129 patients with resectable rectal cancer were enrolled. The primary end points were pathologic response, adverse events, rate of sphincter-sparing surgery, recurrence, and survival. Results: The total dose of tegafur ranged from 21 to 78 (mean, 32) g. The anal sphincter was preserved in 60.5 percent with microscopic no residual tumor (R0). The overall morbidity rate was 32 percent. Wound infection occurred in 13.2 percent of cases and anastomotic leakage in 9 percent of cases. Pathologic responses were observed in 70 percent of patients, with a complete necrosis occurring in 3.9 percent, two-thirds or more necrosis in 6.2 percent, one-third or more but less than two-thirds necrosis in 18.6 percent, and less than one-third necrosis in 41.9 percent. The mean total dose that patients showing complete or two-thirds or more necrosis received was 42.8 ± 6.4 g (P= 0.01) compared with 31.6 ± 1.2 g administered to patients showing less than two-thirds necrosis. Adverse events were observed in 15.6 percent of patients overall, and Grade III or IV events were observed in 2.3 percent of patients. During a median follow-up of 48 months, distant metastasis occurred in 14.7 percent of patients and local recurrence occurred in 6.2 percent of patients. The four-year, disease-free and overall survival rates were 67.6 and 80.1 percent, respectively. Conclusions: Preoperative tegafur suppositories are associated with low toxicity and may lead to analsphincter-sparing surgery with acceptable postoperative complications and favorable local and distal control. Supported in part by the Harnasou Foundation Fund subsidizing Cancer Research in Harunamachi, the Kanetsu Chuo Hospital Research Fund, the Maebashi Norte Hospital Research Fund, the Kato Medical and Surgical Hospital Research Fund in Maebashi, and the Research Fund of the Uchida Clinic in Inamachi, Saitama. Presented in part at the meeting of the American Society of Clinical Oncology, Orlando, FL, May 18 to 21, 2002. E-mail: sohwada@med.gunma-u.ac.jp © The ASCRS 2006...
- Open Access
- 1 April 2006
- Published by Spandidos Publications in Oncology Reports
- Vol. 15 (4) , 861-868
Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: Analysis of immunological parameters
Protein-bound polysaccharide K (PSK) increased the 5-year disease-free survival rate and reduced the risk of recurrence in a randomised, controlled study for stage II and III colorectal cancer. In order to elucidate the disease-free survival benefits with PSK and what immunological markers could indicate a PSK responder, serial changes in immunological parameters were monitored in the study. PSK decreased the mean serum immunosuppressive acidic protein (IAP) level, and increased the mean population of natural killer (NK) cells compared with the controls. The 5-year disease-free and overall survival rate for patients with serum IAP values or=8% at 3 months after surgery, PSK conferred a significantly better (p=0.038) 5-year disease-free survival (86.7%; 95% CI: 74.5-98.8%) compared to the control group (60.0%; 95% CI: 29.6-90.4%). In the proportional hazards model, the presence of regional metastases (relative risk, 3.595; 95% CI: 1.518 to 8.518; p=0.004) and omission of PSK treatment (relative risk, 3.099; 95% CI: 1.202 to 7.990; p=0.019) were significant indicators of recurrence. PSK acts as an immunomodulatory activity and biochemical modulator in stage II or III colorectal cancer. Pre-operative serum IAP values or=8% at 3 months after surgery are possible PSK response predictors.
- 1 April 2006
- Published by Spandidos Publications in Oncology Reports
- Vol. 15 (4) , 861-868
Open AccessBeneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: Analysis of immunological parameters
Protein-bound polysaccharide K (PSK) increased the 5-year disease-free survival rate and reduced the risk of recurrence in a randomised, controlled study for stage II and III colorectal cancer. In order to elucidate the disease-free survival benefits with PSK and what immunological markers could indicate a PSK responder, serial changes in immunological parameters were monitored in the study. PSK decreased the mean serum immunosuppressive acidic protein (IAP) level, and increased the mean population of natural killer (NK) cells compared with the controls. The 5-year disease-free and overall survival rate for patients with serum IAP values or=8% at 3 months after surgery, PSK conferred a significantly better (p=0.038) 5-year disease-free survival (86.7%; 95% CI: 74.5-98.8%) compared to the control group (60.0%; 95% CI: 29.6-90.4%). In the proportional hazards model, the presence of regional metastases (relative risk, 3.595; 95% CI: 1.518 to 8.518; p=0.004) and omission of PSK treatment (relative risk, 3.099; 95% CI: 1.202 to 7.990; p=0.019) were significant indicators of recurrence. PSK acts as an immunomodulatory activity and biochemical modulator in stage II or III colorectal cancer. Pre-operative serum IAP values or=8% at 3 months after surgery are possible PSK response predictors.
- Open Access
- 23 February 2006
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 93 (3) , 339-346
Perioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma
Background: There is no standard method for predicting remnant liver functional reserve after hepatectomy or for monitoring it in real time. Methods: Indocyanine green (ICG) clearance (K) was measured non-invasively and instantaneously using pulse spectrophotometry before surgery, during inflow occlusion and after hepatectomy in 75 patients who underwent anatomical liver resection for hepatocellular carcinoma (HCC). Results: Eight patients (11 per cent) suffered liver failure and one (1 per cent) died in hospital. An estimated remnant K value of 0·090 per min was the cut-off value for liver failure. In a logistic regression model, the estimated remnant K (0·090 per min; P = 0·022) and age (65 years; P = 0·025) were significant predictors of postoperative liver failure. There was a correlation between the estimated and measured post-hepatectomy K, and between the inflow occlusion K and measured post-hepatectomy K (P < 0·001). The cut-off value of less than 0·090 per min for the estimated remnant K resulted in 88 per cent sensitivity and 82 per cent specificity for predicting liver failure. Conclusion: Perioperative real-time monitoring of ICG-K is useful for evaluating the remnant liver functional reserve before, during and after liver resection for HCC. The estimated remnant K is a significant predictor of liver failure.
- 23 February 2006
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 93 (3) , 339-346
Open AccessPerioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma
Background: There is no standard method for predicting remnant liver functional reserve after hepatectomy or for monitoring it in real time. Methods: Indocyanine green (ICG) clearance (K) was measured non-invasively and instantaneously using pulse spectrophotometry before surgery, during inflow occlusion and after hepatectomy in 75 patients who underwent anatomical liver resection for hepatocellular carcinoma (HCC). Results: Eight patients (11 per cent) suffered liver failure and one (1 per cent) died in hospital. An estimated remnant K value of 0·090 per min was the cut-off value for liver failure. In a logistic regression model, the estimated remnant K (0·090 per min; P = 0·022) and age (65 years; P = 0·025) were significant predictors of postoperative liver failure. There was a correlation between the estimated and measured post-hepatectomy K, and between the inflow occlusion K and measured post-hepatectomy K (P < 0·001). The cut-off value of less than 0·090 per min for the estimated remnant K resulted in 88 per cent sensitivity and 82 per cent specificity for predicting liver failure. Conclusion: Perioperative real-time monitoring of ICG-K is useful for evaluating the remnant liver functional reserve before, during and after liver resection for HCC. The estimated remnant K is a significant predictor of liver failure.
- Open Access
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (27) , 4428-4430
Xanthogranulomatous cholangitis causing obstructive jaundice: A case report
Xanthogranulomatous cholangitis causing obstructive jaundice: A case report
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (27) , 4428-4430
Open AccessXanthogranulomatous cholangitis causing obstructive jaundice: A case report
Xanthogranulomatous cholangitis causing obstructive jaundice: A case report
- Open Access
- 10 August 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (6) , 1221-1223
Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
- 10 August 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (6) , 1221-1223
Open AccessReply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
- 9 July 2004
- Vol. 51 (58) , 987-9
Intraoperative massive pulmonary tumor embolism from clear cell sarcoma in the retroperitoneum: successful treatment using cardiopulmonary bypass.
Malignant neoplasms rarely extend into the inferior vena cava and up to the right side of the heart. Although massive pulmonary tumor embolism occurs relatively rarely, it can be a catastrophic problem. Intraoperative pulmonary tumor embolism and cardiac arrest occurred in a 68-year-old woman while dissecting the inferior vena cava to resect a pararenal tumor extending into the retrohepatic inferior vena cava. Abrupt arterial hypotension, tachycardia, and increased central venous pressure lead to the diagnosis of massive pulmonary tumor embolism. Emergency cardiopulmonary bypass was commenced under profound hypothermia and cardiac arrest. The tumors in the main pulmonary artery were extracted, and fragments of remnant tumor were retrieved by a vascular endoscope, a Fogarty catheter, and milking of the lung. Following embolectomy, the tumor in the retrohepatic to infrarenal inferior vena cava was removed and the primary tumor together with the infrarenal inferior vena cava was resected under hepatic vascular exclusion and partial cardiopulmonary bypass. The inferior vena cava below the renal veins was not reconstructed. The patient recovered with slight retrograde amnesia. A postoperative pulmonary perfusion scintigram showed no defect in the pulmonary circulation. She is well now 8 months after surgery. Safe prevention measures should be accomplished as a part of the perioperative management of patients with inferior vena cava tumor thrombus that may be fragile, and cardiopulmonary bypass should always be stand-by on surgery.
- 9 July 2004
- Vol. 51 (58) , 987-9
Intraoperative massive pulmonary tumor embolism from clear cell sarcoma in the retroperitoneum: successful treatment using cardiopulmonary bypass.
Malignant neoplasms rarely extend into the inferior vena cava and up to the right side of the heart. Although massive pulmonary tumor embolism occurs relatively rarely, it can be a catastrophic problem. Intraoperative pulmonary tumor embolism and cardiac arrest occurred in a 68-year-old woman while dissecting the inferior vena cava to resect a pararenal tumor extending into the retrohepatic inferior vena cava. Abrupt arterial hypotension, tachycardia, and increased central venous pressure lead to the diagnosis of massive pulmonary tumor embolism. Emergency cardiopulmonary bypass was commenced under profound hypothermia and cardiac arrest. The tumors in the main pulmonary artery were extracted, and fragments of remnant tumor were retrieved by a vascular endoscope, a Fogarty catheter, and milking of the lung. Following embolectomy, the tumor in the retrohepatic to infrarenal inferior vena cava was removed and the primary tumor together with the infrarenal inferior vena cava was resected under hepatic vascular exclusion and partial cardiopulmonary bypass. The inferior vena cava below the renal veins was not reconstructed. The patient recovered with slight retrograde amnesia. A postoperative pulmonary perfusion scintigram showed no defect in the pulmonary circulation. She is well now 8 months after surgery. Safe prevention measures should be accomplished as a part of the perioperative management of patients with inferior vena cava tumor thrombus that may be fragile, and cardiopulmonary bypass should always be stand-by on surgery.
- Open Access
- 2 March 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (5) , 1003-1010
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study
Intravenous fluorouracil and leucovorin is the standard adjuvant treatment for stage III colon cancer. However, oral adjuvant chemotherapy is attractive because it has low toxicity and greater convenience. We investigated the benefits of oral protein-bound polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer. Patients were assigned to groups that received either 3 g PSK plus 300 mg UFT, or 300 mg UFT alone orally each day for a 2-year period following intravenous mitomycin C. Of 207 registered patients, 205 with stage II (n=123) or III (n=82) were analysed. The 5-year disease-free survival was 73.0% (95% CI 65.6–80.4%) with PSK (n=137) and 58.8% (95% CI 47.1–70.5%) in the controls (n=68) (P=0.016). Polysaccharide K reduced the recurrence by 43.6% (95% CI 4.5–66.7%) and mortality by 40.2% (95% CI −12.5 to 68.3%). The 5-year survival was 81.8% (95% CI 75.3–88.2%) in the PSK group and 72.1% (95% CI 61.4–82.7%) in the control group (P=0.056). In stage III patients, disease-free and overall survivals in patients receiving PSK were increased significantly: 60.0% (95% CI 47.1–72.9%) and 74.6% (95% CI 63.0–86.1%) in the PSK group as compared with 32.1% (95% CI 14.8–49.4%) and 46.4% (95% CI 28.0–64.9%) in the controls (P=0.002 and 0.003, respectively). Polysaccharide K prevented recurrence, particularly lung metastases (P=0.02; odds ratio 0.27; 95% CI 0.09–0.77). In the models, the presence of regional metastases (relative risk, 2.973; 95% CI 1.712–5.165; PP=0.007), and higher primary tumour (relative risk, 4.398; 95% CI 1.017–19.014; P=0.047) were each significant indicators of recurrence. Adverse effects were mild and compliance was good. Oral PSK with UFT reduced recurrence in stage II and III colorectal cancer, and increased survival in stage III.
- 2 March 2004
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (5) , 1003-1010
Open AccessAdjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study
Intravenous fluorouracil and leucovorin is the standard adjuvant treatment for stage III colon cancer. However, oral adjuvant chemotherapy is attractive because it has low toxicity and greater convenience. We investigated the benefits of oral protein-bound polysaccharide K (PSK) with tegafur/uracil (UFT) as an adjuvant in stage II and III colorectal cancer. Patients were assigned to groups that received either 3 g PSK plus 300 mg UFT, or 300 mg UFT alone orally each day for a 2-year period following intravenous mitomycin C. Of 207 registered patients, 205 with stage II (n=123) or III (n=82) were analysed. The 5-year disease-free survival was 73.0% (95% CI 65.6–80.4%) with PSK (n=137) and 58.8% (95% CI 47.1–70.5%) in the controls (n=68) (P=0.016). Polysaccharide K reduced the recurrence by 43.6% (95% CI 4.5–66.7%) and mortality by 40.2% (95% CI −12.5 to 68.3%). The 5-year survival was 81.8% (95% CI 75.3–88.2%) in the PSK group and 72.1% (95% CI 61.4–82.7%) in the control group (P=0.056). In stage III patients, disease-free and overall survivals in patients receiving PSK were increased significantly: 60.0% (95% CI 47.1–72.9%) and 74.6% (95% CI 63.0–86.1%) in the PSK group as compared with 32.1% (95% CI 14.8–49.4%) and 46.4% (95% CI 28.0–64.9%) in the controls (P=0.002 and 0.003, respectively). Polysaccharide K prevented recurrence, particularly lung metastases (P=0.02; odds ratio 0.27; 95% CI 0.09–0.77). In the models, the presence of regional metastases (relative risk, 2.973; 95% CI 1.712–5.165; PP=0.007), and higher primary tumour (relative risk, 4.398; 95% CI 1.017–19.014; P=0.047) were each significant indicators of recurrence. Adverse effects were mild and compliance was good. Oral PSK with UFT reduced recurrence in stage II and III colorectal cancer, and increased survival in stage III.